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Both during normal physiological development 
as well as in the face of cardiac stress, the heart 
exhibits enormous plasticity in growth, remodeling, and 
atrophy. Central to this adaptive ability is the heart’s 
metabolic capacity to react quickly both anabolically 
and catabolically in order to maintain cardiac output. 
In response to hemodynamic stress, the heart adapts to 
maintain overall contractile function via pathological 
remodeling that often includes cardiomyocyte hypertrophy 
as well as changes in cardiomyocyte metabolism that 
eventually lead to contractile dysfunction and heart 
failure. It is unclear as to whether the metabolic changes 
that accompany pathological hypertrophy are adaptive 
or maladaptive; however, as in most complex biological 
systems, the answer likely resides somewhere in the 
middle. Goodwin et al. demonstrated in 1998 that 
hemodynamic stress increases carbohydrate use for 
ATP generation and induces cardiac remodeling [1]. 
Numerous subsequent studies have attributed the change 
in metabolism and cardiac remodeling to activation of the 
mammalian (or mechanistic) target of rapamycin (mTOR), 
a kinase that is a primary regulator of myocardial protein 
synthesis. Recent experimental models that manipulate 
cardiac metabolism and mTOR signaling have provided 
new insights into the relationship between metabolic 
and structural remodeling (reviewed in detail by Kundu 
et al. [2]). One hopes that such models will identify 
metabolic changes that precede remodeling in order to find 
therapeutic targets for cardiac disease.
We developed a mouse model of heart-specific 
inactivation of ACSL1, a membrane-associated enzyme 
present on the mitochondria and endoplasmic reticulum 
that catalyzes the activation of long-chain fatty acids to 
form acyl-CoAs [3]. The ACSL1 isoform appears to deliver 
newly formed acyl-CoAs to carnitine palmitoyltransferase, 
thereby targeting them for mitochondrial β-oxidation. 
As a result of ASCL1 inactivation, fatty acids can no 
longer be oxidized to contribute to ATP synthesis, and 
hearts undergo a dramatic switch to glucose metabolism 
as their primary source of energy [3]. Although Acsl1H-/- 
mice develop mTOR-dependent cardiac hypertrophy, 
surprisingly, the cardiac function of Acsl1H-/- mice remains 
resilient. After 20 weeks of ACSL1 inactivation, systolic 
function remains unaffected [3] even in the presence of 
early stage diastolic dysfunction [4]. Systolic heart failure 
is commonly observed in other models in which mTOR 
activity is increased, more specifically mTORC1 [5], 
or when reliance on glucose metabolism is forced (for 
examples see Schisler et al. [6]). Because Acsl1H-/- mice 
do not develop systolic heart failure, our mice provide a 
useful model to identify genes and metabolites that may 
contribute specifically to diastolic dysfunction or to the 
maintenance of systolic function and decreased cardiac 
mortality even when mTOR is markedly activated. 
First, our data [6] support recent studies 
demonstrating that cardiac metabolic remodeling 
precedes the hypertrophic response. In an unbiased 
approach, we observed multiple glycolytic metabolites 
such as glucose 6-phosphate, mannose 6-phosphate, and 
fructose 6-phosphate that are likely to contribute to the 
activation of mTOR. Additionally, metabolomics profiling 
of Acsl1H-/- hearts also revealed a surprising increase 
in 13 metabolites related to cysteine and glutathione 
metabolism. We hypothesize that the upregulation of 
glutathione metabolism may be a response to a selective, 
glutathione-restricted oxidative stress observed after 10 
weeks of ACSL1 inactivation. Dietary supplementation 
can modulate the cysteine-glutathione pathway in animal 
models [7] and in vivo studies that modify this pathway 
should provide further insight into whether cysteine-
glutathione metabolism is, in fact, cardioprotective 
when mTOR is activated. In addition, we identified the 
up-regulation of several starvation-related atrophy genes 
that contain amino acid response elements, as well as 
multiple genes associated with amino acid deprivation. 
Although the increased expression of these genes, 
including the atrogene MuRF1, are usually associated 
with atrophy and loss of skeletal muscle mass, we may 
be observing an unappreciated component of cardiac 
metabolic reprogramming that uses selective protein 
catabolism to maintain cardiac output, undeterred by 
mTORC1-induced protein synthesis. Furthermore, the 
finding that mTORC1-inhibited autophagy is prominent 
in Acsl1H-/- hearts (Grevengoed and Coleman et al., 
unpublished observations), suggests not only alternative 
mechanisms of protein degradation, but also highlights the 
preserved systolic function despite structurally abnormal 
mitochondria with diminished respiratory function. 
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